Ibrutinib suppresses LPS-induced neuroinflammatory responses in BV2 microglial cells and wild-type mice

BACKGROUND: The FDA-approved small-molecule drug ibrutinib is an effective targeted therapy for patients with chronic lymphocytic leukemia (CLL). Ibrutinib inhibits Bruton’s tyrosine kinase (BTK), a kinase involved in B cell receptor signaling. However, the potential regulation of neuroinflammatory...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Neuroinflammation
Main Authors: Nam, Hye Yeon, Nam, Jin Han, Yoon, Gwangho, Lee, Ju-Young, Nam, Youngpyo, Kang, Hye-Jin, Cho, Hyun-Ji, Kim, Jeongyeon, Hoe, Hyang-Sook
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2018
Assuntos:
Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6145206/
https://ncbi.nlm.nih.gov/pubmed/30231870
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12974-018-1308-0
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares